Navigation Links
Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
Date:1/8/2009

SAN FRANCISCO, Jan. 8 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the 27th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, at 10:00 a.m. Pacific Time at the Westin St. Francis Hotel in San Francisco.

Dr. Hung will provide an overview of Medivation and its clinical development programs for Dimebon for Alzheimer's and Huntington's diseases and MDV3100 for prostate cancer.

A live audio webcast will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation entered into a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The program also includes additional trials planned to begin this year in Alzheimer's disease, as well as further development of Dimebon in patients with mild-to-moderate Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
2. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
3. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
4. Medivation Announces Participation in Upcoming Conferences
5. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
6. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
7. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
8. HEI, Inc. Announces Sale of RFID Division Assets
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
11. Z Trim Announces Revocation of Gregory Halpern Severence Agreement

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)... Tonight the House of Re...r America Act, landmark health reform legislation ...ity, affordable, stable and secure health care cov...of the insurance industry,s worst practices, would...he deficit by $104 billion over ten years. Groups ...
(Date:11/8/2009)... Freeze-drying of biopharmaceuticals to be availab...ility. , Toronto, ON (PR... and CEO of Therapure Biopharma Inc. today announc...cial scale pharmaceutical grade freeze dryer and e...philization) available for contract manufacturing ...
(Date:11/8/2009)... Today, the House of Rep...lkemper, Smith, Ellsworth and Lipinski amendment t...R. 3962). The amendment maintains the current poli...for benefits packages that include abortion. It cl...ffordability credits and those who do not, can wit...
(Date:11/8/2009)... USAction this evening h...erica Act, which will make health care more afford...ntable and increase access to health care for mill...Teddy Roosevelt, FDR and Harry Truman would be pro..."Today,s vote ranks among our country,s proudest a...
(Date:11/8/2009)... The following was relea...scue Insurrecta Nex. ,, Mr. Terry and his asso...to keep child-killing by abortion out of any healt...his is a great first step to victory -- a touchdow...hting ahead of us. Our rejoicing must be tempered ...
Breaking Medicine News(10 mins):Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 2Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 3Health News:Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer 2Health News:Family Research Council Praises Passage of Pro-life Amendment to Health Care Bill 2
...la., Nov. 20 The State of Arkansas,Department of ...elected,U.S. Care Management (formally Specialty D...nt health management services to assist in improvi...tenden, Phillips and St. Francis Counties, Arkansa...
...f., Nov. 20 2007 Vase or face" When presented wit...either a vase or the faces of two people, what we ... going on in our brains. , In this example, whe... UC Irvine cognitive neuroscientist. , In a rece...
...ood volume produced in the obese may so dilute lev...at the popular PSA test may be essentially useless...tra pounds, a new study in The Journal of the Amer...and elsewhere, could eventually affect the reliabi...
...ts their higher blood volume explains it , ...years, doctors have learned that they need to adju... prostate cancer in obese men, but now researchers...e trouble. , The new study doesn,t definitively pr...
...family of products offers formulas of essential pr...n, SAN ANTONIO, Nov. 20 Mission Pharmacal today ...of prescription prenatal vitamins.,The CitraNatal ...iod. These new products include CitraNatal(TM) DHA...
... for parents to teach children how to keep hands c...inutes, a child puts a hand in his/her nose or mou... live two hours or longer on surfaces like,cafeter...ng to the Centers for Disease Control and Preventi...
Other Medicine News:Health News:State of Arkansas Department of Human Services, Division of Medical Services Selects U.S. Care Management for High-Risk Obstetrics Health Management Program 2Health News:State of Arkansas Department of Human Services, Division of Medical Services Selects U.S. Care Management for High-Risk Obstetrics Health Management Program 3Health News:State of Arkansas Department of Human Services, Division of Medical Services Selects U.S. Care Management for High-Risk Obstetrics Health Management Program 4Health News:Scientists uncover how the brain controls what the eyes see 2Health News:Obesity-linked high blood volumes render PSA prostate cancer test less effective, study suggests 2Health News:Why Obese Men Post Lower PSA Levels 2Health News:Mission Pharmacal Launches CitraNatal(TM) Prescription Prenatal Vitamin Line 2Health News:Proper Hand Hygiene Is Key to Avoiding Illness During Cold and Flu Season 2
(Date:11/6/2009)...M, N.C., Nov. 6 Oxygen B...day announced that a previously approved reverse s...tart of trading on Monday, Nov. 9, 2009 on a 1-for...Inc. shares will trade under the new symbol OXBT. ...P 20 9, when the split becomes effective. ,, "T...
(Date:11/6/2009)...STOWN, N.J., Nov. 6 Wats...specialty pharmaceutical company, announced today ...cutive officer, will provide an overview and updat...8th Annual Healthcare Conference on Wednesday, Nov...,, This presentation will be webcast live and c...
(Date:11/6/2009)...ESTON, S.C., Nov. 6 T...g in South Carolina and Georgia throughout the wee...elp uninsured and financially-struggling patients ...iption medicines for free or nearly free. With the...nt, the Partnership for Prescription Assistance (P...
Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 2Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 3Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 2Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 3Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 1Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 2Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 3Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 4New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 1New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 2New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 3New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 4New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 5Get Ready for Ragweed 55647 1Get Ready for Ragweed 55647 2
... Italy, April 26 Schering-Plough Corporation,(NYS...ed interim analysis of,an ongoing Phase II study o... protease inhibitor, in 595 treatment-naive patien... were presented at the 43rd Annual,Meeting of the ...ASL). The,ongoing study evaluates boceprevir in 28...
...Large Study Comparing Leading Hepatitis C Therapie...ide Clinical Practice, MILAN, Italy, April 26 Fi...andomized, clinical study comparing the,leading th...day at the 43rd,Annual Meeting of the European Ass...ing important insights that may help guide clinica...
Other Medicine Technology:Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 3Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 4Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 6Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 7Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 8Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 9Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 2Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 3Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 4Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 5Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 6Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 7Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 8Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 9Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 10
...a laser system with one single wavelength of 1064n...us intensities of either 60 W or 100 W, and it is ...ues. This laser is the classical version of Smart1...tals and clinics which would like to have a versat...
SmartChill
...been designed exclusively for vascular treatments,...epil range which ensures fast amortisation of the ...ems, it can be fitted with a polarised light viewi... target to be treated as well as the operators max...
...:YAG) laser is the ideal instrument for safe, repe...s, the majority of surface lesions can be treated,...e, with a minimum of heat damage and in most cases...dverse side effects. Smart 2940 Plus incorporates ...
Medicine Products: